Yinjia pill inhibits persistent Chlamydia trachomatis infection  

作　　者：Mei Luo Rongjing Hu Ziyi Zhao Lanshuang Li Ming Xia 

机构地区：[1]Department of Gynecology,Chongqing Hospital of Traditional Chinese Medicine,Chongqing 402760,China [2]The Fourth School of Clinical Medicine,Chengdu University of Traditional Chinese Medicine,Chengdu,Sichuan 610032,China [3]Affiliated Hospital of Chengdu University of Traditional Chinese Medicine,Chengdu,Sichuan 610072,China

出　　处：《Chinese Medical Journal》2022年第23期2893-2895,共3页中华医学杂志（英文版）

基　　金：the Natural Science Foundation of Chongqing(No.cstc2020jcyjmsxmX1030);the Xinglin Scholar Research Premotion Project of Chengdu University of TCM(No.YYZX20180049);the Chongqing Science and Technology Department Project(No.cstc2018jxjll30065).

摘　　要：To the Editor:Chlamydia trachomatis(C.trachomatis)is obligate intracellular pathogens,often resulting in development of chronic disease and tissue damage as a consequence of the host inflammatory immune response as well as persistent infections,[1]which is associated with the activation of mitogen-activated protein kinase(MAPK)and extracellular regulated protein kinases(ERK)mediated by Toll-like receptors(TLRs)and myeloid differentiation primary response gene 88(MyD88).[2]Furthermore,C.trachomatis has evolved the ability to block the apoptosis of its host cells involving the interaction of autophagy and apoptosis.[3]Novel strategies to prevent and treat C.trachomatis infection effectively are needed.

关 键 词：TRACHOMATIS CHLAMYDIA INFECTION 

分 类 号：R285[医药卫生—中药学]